Related references
Note: Only part of the references are listed.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau et al.
LANCET ONCOLOGY (2022)
Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
Ligong Lu et al.
HEPATOLOGY (2021)
Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma
Huayu Yang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells
Ting Liu et al.
GUT (2021)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
Zhixiong Cai et al.
MOLECULAR CANCER (2021)
PERSONALIZED DNA NEOANTIGEN VACCINE (GNOS-PV02) IN COMBINATION WITH PLASMID IL-12 AND PEMBROLIZUMAB FOR THE TREATMENT OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Mark Yarchoan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
Pu Chen et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)
Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances
Jimmy Charneau et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
Zobair M. Younossi et al.
JHEP REPORTS (2021)
Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Thomas Yau et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Advances in molecular classification and precision oncology in hepatocellular carcinoma
Sandra Rebouissou et al.
JOURNAL OF HEPATOLOGY (2020)
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
Robin Kate Kelley et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses
Diana Campillo-Davo et al.
CELLS (2020)
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naive Patients with Diverse Cancers
Paul Riviere et al.
MOLECULAR CANCER THERAPEUTICS (2020)
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
Patrick A. Ott et al.
CELL (2020)
Identification of neoantigen-reactive T cells in hepatocellular carcinoma: implication in adoptive T cell therapy
Enric Vercher et al.
JOURNAL OF HEPATOLOGY (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial
Jin Won Youn et al.
LANCET ONCOLOGY (2020)
Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma
Leyre Silva et al.
CANCERS (2020)
Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease
Diwakar Suresh et al.
FRONTIERS IN ONCOLOGY (2020)
Regulatory T cells in cancer immunosuppression - implications for anticancer therapy
Yosuke Togashi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
Markus W. Loeffler et al.
GENOME MEDICINE (2019)
Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas
Qi Zhang et al.
GUT (2019)
LBA39Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
M Lee et al.
ANNALS OF ONCOLOGY (2019)
327PNeoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
X Liu et al.
ANNALS OF ONCOLOGY (2019)
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer A Phase 2 Clinical Trial
Erminia Massarelli et al.
JAMA ONCOLOGY (2019)
Cancer Neoantigens
Ton N. Schumacher et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 37, 2019 (2019)
High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy
Angela Mauriello et al.
CANCERS (2019)
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf et al.
NATURE (2019)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin et al.
NATURE (2019)
Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification
Yutaka Kurebayashi et al.
HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity
Shishir Shetty et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Hepatic Dendritic Cells, the Tolerogenic Liver Environment, and Liver Disease
Lei Dou et al.
SEMINARS IN LIVER DISEASE (2018)
Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment
Sindy Vrecko et al.
Oncotarget (2018)
Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients
Annacarmen Petrizzo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression
Qiong-Fang Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2017)
The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
M. O. Holmstrom et al.
LEUKEMIA (2017)
Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein - Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma
Hidetoshi Nakagawa et al.
GASTROENTEROLOGY (2017)
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
Else M. Inderberg et al.
ONCOIMMUNOLOGY (2017)
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Adrian Ally et al.
CELL (2017)
Liver macrophages in tissue homeostasis and disease
Oliver Krenkel et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Developments in cancer vaccines for hepatocellular carcinoma
Luigi Buonaguro
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression
Tobias Eggert et al.
CANCER CELL (2016)
Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib
Shao-Lai Zhou et al.
GASTROENTEROLOGY (2016)
Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy
Abhijeet Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Neoantigen landscape dynamics during human melanoma-T cell interactions
Els M. E. Verdegaal et al.
NATURE (2016)
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer
Akihiro Fujimoto et al.
NATURE GENETICS (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
A large fraction of HLA class I ligands are proteasome-generated spliced peptides
Juliane Liepe et al.
SCIENCE (2016)
Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames
Celine M. Laumont et al.
NATURE COMMUNICATIONS (2016)
PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression
Xiao Xiao et al.
CANCER DISCOVERY (2016)
Cancer cell-derived IL-1 induces CCL22 and the recruitment of regulatory T cells
Gabriela Maria Wiedemann et al.
ONCOIMMUNOLOGY (2016)
Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments
Elisabetta Cariani et al.
ONCOIMMUNOLOGY (2016)
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
Yu Sawada et al.
ONCOIMMUNOLOGY (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
Jeong-Hoon Lee et al.
BRITISH JOURNAL OF CANCER (2015)
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
Kornelius Schulze et al.
NATURE GENETICS (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma
Carsten Linnemann et al.
NATURE MEDICINE (2015)
Human CD14+CTLA-4+ Regulatory Dendritic Cells Suppress T-Cell Response by Cytotoxic T-Lymphocyte Antigen-4-Dependent IL-10 and Indoleamine-2,3-Dioxygenase Production in Hepatocellular Carcinoma
Yanmei Han et al.
HEPATOLOGY (2014)
Immunodominance and Functional Alterations of Tumor-Associated Antigen-Specific CD8+ T-Cell Responses in Hepatocellular Carcinoma
Tobias Flecken et al.
HEPATOLOGY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Mahesh Yadav et al.
NATURE (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
HLA-Binding Properties of Tumor Neoepitopes in Humans
Edward F. Fritsch et al.
CANCER IMMUNOLOGY RESEARCH (2014)
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
Marit M. van Buuren et al.
ONCOIMMUNOLOGY (2014)
Dendritic cell-targeted vaccines - hope or hype?
Wolfgang Kastenmueller et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
Fumitaka Arihara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus-Related Hepatocellular Carcinoma
Elisabetta Cariani et al.
CLINICAL CANCER RESEARCH (2013)
Impairment of CD4+ Cytotoxic T Cells Predicts Poor Survival and High Recurrence Rates in Patients With Hepatocellular Carcinoma
Junliang Fu et al.
HEPATOLOGY (2013)
TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis
Tokuhiro Matsubara et al.
HEPATOLOGY (2013)
Potential therapeutic value of dendritic cells loaded with NY-ESO-1 protein for the immunotherapy of advanced hepatocellular carcinoma
Yuqing Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2013)
Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion
Bastian Hoechst et al.
JOURNAL OF HEPATOLOGY (2013)
Hepatic Stellate Cells Preferentially Induce Foxp3+ Regulatory T Cells by Production of Retinoic Acid
Richard M. Dunham et al.
JOURNAL OF IMMUNOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
MHC Class I-Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia
Mark Cobbold et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Exploiting the Mutanome for Tumor Vaccination
John C. Castle et al.
CANCER RESEARCH (2012)
Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
Yu Sawada et al.
CLINICAL CANCER RESEARCH (2012)
Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses
Fei Zhao et al.
JOURNAL OF IMMUNOLOGY (2012)
Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma
Elisabetta Cariani et al.
PLOS ONE (2012)
The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed
Jelena Popovic et al.
BLOOD (2011)
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2011)
An antigenic peptide produced by reverse splicing and double asparagine deamidation
Alexandre Dalet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
Tim F. Greten et al.
BMC CANCER (2010)
Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
Ke Wu et al.
CANCER RESEARCH (2009)
Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
Yujin Hoshida et al.
CANCER RESEARCH (2009)
Systemic Therapies in Hepatocellular Carcinoma
Marcus Alexander Woerns et al.
DIGESTIVE DISEASES (2009)
A Phase II Study of Adoptive Immunotherapy Using Dendritic Cells Pulsed with Tumor Lysate in Patients with Hepatocellular Carcinoma
Daniel H. Palmer et al.
HEPATOLOGY (2009)
Myeloid Derived Suppressor Cells Inhibit Natural Killer Cells in Patients with Hepatocellular Carcinoma via the NKp30 Receptor
Bastian Hoechst et al.
HEPATOLOGY (2009)
Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients
Jia Zhou et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Enrichment of Human CD4+ Vα24/Vβ11 Invariant NKT Cells in Intrahepatic Malignant Tumors
Gabriel Bricard et al.
JOURNAL OF IMMUNOLOGY (2009)
Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
Mei-Hwei Chang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Liver sinusoidal endothelial cells veto CD8 T cell activation by antigen-presenting dendritic cells
Frank A. Schildberg et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells
Bastian Hoechst et al.
GASTROENTEROLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients
Junliang Fu et al.
GASTROENTEROLOGY (2007)
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Sandrine Boyault et al.
HEPATOLOGY (2007)
Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma
H Komori et al.
CLINICAL CANCER RESEARCH (2006)
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides
LH Butterfield et al.
CLINICAL CANCER RESEARCH (2006)
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
V Lennerz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection
A López-Vázquez et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma
LA Ormandy et al.
CANCER RESEARCH (2005)
Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma
G Bricard et al.
JOURNAL OF IMMUNOLOGY (2005)
Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells - A clinical trial
WC Lee et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
JS Lee et al.
HEPATOLOGY (2004)
Immunogenicity of constitutively active V599EBRaf
MH Andersen et al.
CANCER RESEARCH (2004)
Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma
F Korangy et al.
CLINICAL CANCER RESEARCH (2004)
Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma
A Zerbini et al.
JOURNAL OF HEPATOLOGY (2004)
A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer
Y Iwashita et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2003)
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:: a randomised controlled trial
JM Llovet et al.
LANCET (2002)
Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant
RE Hunger et al.
EXPERIMENTAL DERMATOLOGY (2001)
Share Paper
